{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:48:27Z","timestamp":1793832507656,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bulcan.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T17:07:22Z","timestamp":1653498442000},"page":"826-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Urinary toxicity in patients treated with radical EBRT for prostate cancer: Analysis of predictive factors in an historical series"],"prefix":"10.1016","volume":"109","author":[{"given":"Carla","family":"Pisani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Beld\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Krengli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2022.03.011_bib0180","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1590\/S1677-5538.IBJU.2014.03.05","article-title":"Tailored treatment including radical prostatectomy and radiation therapy+androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study","volume":"40","author":"Castelli","year":"2014","journal-title":"Int Braz J Urol"},{"issue":"7","key":"10.1016\/j.bulcan.2022.03.011_bib0185","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.25467","article-title":"Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer","volume":"117","author":"Alicikus","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0190","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU\u2013ESTRO\u2013SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13014-016-0599-5","article-title":"Beyond D\u2019Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier","volume":"11","author":"Gabriele","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0200","unstructured":"NCCN Guideline\u2013Prostate cancer, Version 2.21; http:\/\/nccn.org."},{"key":"10.1016\/j.bulcan.2022.03.011_bib0205","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","article-title":"Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial","volume":"64","author":"Pollack","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0210","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0215","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijrobp.2005.10.002","article-title":"Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer","volume":"64","author":"Peeters","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0220","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcome and complications following radiation therapy for prostate cancer: a critical analysis of the literature","volume":"61","author":"Budaus","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0225","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2015.07.048","article-title":"Multivariable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: results of a cohort study","volume":"116","author":"Cozzarini","year":"2015","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2022.03.011_bib0230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmp.2016.03.003","article-title":"Predicting toxicity in radiotherapy for prostate cancer","volume":"32","author":"Landoni","year":"2016","journal-title":"Phys Med"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0235","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0245","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0250","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.bulcan.2022.03.011_bib0255","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0260","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0265","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1464-410X.2006.05885.x","article-title":"Italian validation of the Internationl Consultation on Incontinence Questionnaires","volume":"97","author":"Tubaro","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2013.07.041","article-title":"Preliminary toxicity analysis of 3-dimensional conformal radiation therapy vs. intensity-modulated radiation therapy on the high-dose arm of the RTOG0126 prostate cancer trial","volume":"87","author":"Michalski","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0330","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmp.2016.03.003","article-title":"Predicting toxicity in radiotherapy for prostate cancer","volume":"32","author":"Landoni","year":"2016","journal-title":"Phys Med"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0275","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ijrobp.2010.03.040","article-title":"External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS)","volume":"80","author":"Malik","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0280","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","article-title":"Urinary obstruction in prostate cancer patients from the Dutch trial (68Gy vs. 78Gy): relationships with local dose, acute effects, and baseline characteristics","volume":"78","author":"Heemsbergen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0285","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2014.04.005","article-title":"Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions","volume":"112","author":"De Langhe","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0290","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.radonc.2014.02.006","article-title":"Relationships between bladder dose\u2013volume\/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer","volume":"111","author":"Carillo","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0295","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.06.011","article-title":"Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: an analysis of data from the RADAR prostate radiotherapy trial","volume":"116","author":"Yahya","year":"2015","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.03.011_bib0300","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2015.11.036","article-title":"Multivariable models of large IPSS worsening at the end of therapy in prostate cancer radiotherapy","volume":"118","author":"Palorini","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13014-016-0734-3","article-title":"Three-dimensional surface and ultrasound imaging for daily IGRT of prostate cancer","volume":"11","author":"Krengli","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0310","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.prro.2012.04.005","article-title":"Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy","volume":"3","author":"Ali","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0315","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clon.2011.03.001","article-title":"The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397)","volume":"23","author":"Barnett","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1748-717X-5-27","article-title":"Consequential late effects after radiotherapy for prostate cancer\u2013a prospective longitudinal quality of life study","volume":"5","author":"Pinkawa","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0335","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.acuro.2017.03.010","article-title":"Predictor of urinary and rectal toxicity after external conformed radiation therapy in prostate cancer: correlation between clinical, tumour and dosimetric parameters and radical and postoperative radiation therapy","volume":"41","author":"Martinez-Arribas","year":"2017","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0325","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2015.11.036","article-title":"Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy","volume":"118","author":"Palorini","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0340","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2020.02.028","article-title":"Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: assessment of cohort and method effects","volume":"147","author":"Mylon","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13014-017-0839-3","article-title":"Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity","volume":"12","author":"Jolnerovski","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.bulcan.2022.03.011_bib0350","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11547-019-01082-0","article-title":"CT imaging markers to improve radiation toxicity prediction in prostate cancer radiotherapy by stacking regression algorithm","volume":"125","author":"Mostafaei","year":"2020","journal-title":"Radiol Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:41Z","timestamp":1757792141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":34,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0007455122001503"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.03.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary toxicity in patients treated with radical EBRT for prostate cancer: Analysis of predictive factors in an historical series","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}